Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DALICATH trial of single-dose dalbavancin versus standard antibiotics for uncomplicated catheter-related Staphylococcus aureus bloodstream infection
2024-514952-34-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2024
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dalbavancin in catheter-associated bloodstream infection (CRBSI) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Clinical cure without relapse at Day 30. Planned start Sep 2024; status: authorised.
02
Drugs
dalbavancin
03
Conditions
catheter-associated bloodstream infection (CRBSI)
Beyond the preview
Go deeper on 2024-514952-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514952-34-00.